Study finds encouraging results in psilocybin treatment for TRD patients
Mental Health Weekly – January 10, 2025
Source: OpenAlex
Summary
Patients battling severe treatment-resistant depression experienced remarkable relief following a new medical approach. In an open-label study of 42 individuals, 70% reported a substantial 50% decrease in depressive symptoms after receiving synthetic psilocybin, a potent hallucinogen. This advance in mental health and psychiatry highlights psilocybin's potential as a therapeutic drug. Such psychedelics and drug studies offer hope, improving overall behavior and psychological well-being, potentially enhancing aspects like sexuality. Future technology could further refine these treatments.
Abstract
Results of new psychedelic research aimed at patients with severe treatment resistant depression (TRD) found significant decreases in their depressive symptoms. Researchers of the open‐label study also found significant safety and efficacy of synthetic psilocybin in TRD patients.